Partners in Financial Planning Purchases New Stake in Edwards Lifesciences Co. (NYSE:EW)

Partners in Financial Planning bought a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,584 shares of the medical research company's stock, valued at approximately $858,000.

Several other hedge funds also recently modified their holdings of the stock. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $29,000. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the fourth quarter worth $30,000. Finally, Roble Belko & Company Inc purchased a new position in Edwards Lifesciences in the fourth quarter worth $46,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group raised their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research report on Thursday, February 13th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Barclays raised their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Finally, Citigroup lifted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $79.95.

Remove Ads

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded down $1.62 on Friday, hitting $71.36. The company's stock had a trading volume of 2,542,735 shares, compared to its average volume of 4,507,805. The company has a market capitalization of $41.95 billion, a PE ratio of 10.22, a PEG ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a 50-day simple moving average of $71.73 and a 200 day simple moving average of $70.62. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares of the company's stock, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,553 shares of company stock valued at $4,513,064 over the last 90 days. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.